Apple’s Starlink Update Sparks Huge Earning Opportunity

Apple’s Starlink Update Sparks Huge Earning Opportunity

Apple just secretly added Starlink satellite support to iPhones through iOS 18.3.

One of the biggest potential winners? Mode Mobile.

Mode’s EarnPhone already reaches 490M+ users that have earned over $1B, and that’s before global satellite coverage. With SpaceX eliminating “dead zones,” Mode’s earning technology can now reach billions more in unbanked and rural populations worldwide.

Their global expansion is perfectly timed, and investors like you still have a chance to invest in their pre-IPO offering at $0.50/share.

With their recent 32,481% revenue growth and newly reserved Nasdaq ticker, Mode is one step closer to a potential IPO.

Today is the last day to invest at $0.50/share. 

Please read the offering circular at invest.modemobile.com. This is a paid advertisement for Mode Mobile’s Regulation A Offering.

This might sound familiar…

Ever feel like you’re always one step behind the market? You spot the move… hesitate… and by the time you act, it’s gone. That’s the cycle most traders get stuck in. But my unique approach flips that. 

Instead of reacting, it’s built around pre-defined setups and timing windows – so you’re not chasing. You’re prepared. It’s a simple shift, but it changes everything. [ad]

See how it works here.Iran War Shock: What I Was Told In That Private Meeting

On January 7th… just outside Washington, D.C… I sat across from a man whose family has been tied to global power for decades.

Oil deals. Intelligence circles. Government insiders.

He leaned in and told me something that changed everything I thought I knew about the Iran war.

What you’re seeing on the news? It’s not the real story.

The strikes… the chaos… the escalation…It’s all part of something much bigger.

And the only reason I know this is because of him – an anonymous contact who risked everything to pass this information along.

Click here to see the full breakdown before it’s too late.
Replimune to resubmit twice-rejected drug for approval after FDA shakeup

  • Replimune was among the drugmakers that had criticized the FDA for what they called inconsistent guidance around trials and approvals.

Privacy Policy | Advertiser DisclosureDISCLAIMER: Stocks and options trading have large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stocks and options markets. Don’t trade with money you can’t afford to lose. This is neither a solicitation nor an offer to Buy/Sell stocks or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed in this report. The past performance of any trading system or methodology is not necessarily indicative of future results. All trades, patterns, charts, systems, etc., discussed in this report are for illustrative purposes only and not to be construed as specific advisory recommendations. Information contained in this correspondence is intended for informational purposes only and was obtained from sources believed to be reliable. Information is in no way guaranteed. No guarantee of any kind is implied or possible where projections of future conditions are attempted.

Stockguru LLC (dba InvestingDistrict), 2563 cherry hill ln, Hermitage, PA 16148, United StatesYou may unsubscribe or change your contact details at any time.

Leave a Comment